Company intelligence / Profile preview

D.G. I.I.

Ownership: Private
Development stage: Commercial

Overview

Dei BioPharma is pioneering pharmaceutical manufacturing in Africa with a state-of-the-art facility adhering to US FDA, EU EMA, and WHO GMP standards. The company’s lead program involves an FDA-reviewed biological drug targeting diabetes and weight loss via GLP-1 receptor agonism. They are also building capacity for innovative medicines and vaccines using advanced RNA technologies.

Therapeutic areas: Endocrinology
Modalities: Small moleculeRNA-based drugsVaccineBiologic
Industry: Biotech

Beyond the preview

Go deeper on D.G. I.I..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D.G. I.I..

Explore the full profile